CYP3A5

Across TCGA pan-cancer cohorts, CYP3A5 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CYP3A5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CYP3A5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CYP3A5 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where CYP3A5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP3A5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−1.800	<.001	5	view →
LSCC	All	All	−1.183	.002	4	view →
PDAC	Female	All	+0.674	.016	4	view →
LUAD	Female	All	−0.523	.043	1	view →
COAD	All	III,IV	−0.482	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CYP3A5–HNSC

Open the HNSC breakdown →